Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis.
Gerd R BurmesterLaura C CoatesStanley B CohenYoshiya TanakaIvana VranicEdward NagyIrina LazariciuAll-Shine ChenKenneth KwokLara FallonCassandra D KinchPublished in: Rheumatology and therapy (2023)
Tofacitinib PMS safety data from submitted AE reports were consistent between PsA and RA, and aligned with its known safety profile. Exposure data (lower MR versus IR; estimation from commercial sales data), reporting bias, reporter identity, and regional differences in formulation use limit interpretation.
Keyphrases
- rheumatoid arthritis
- electronic health record
- disease activity
- big data
- prostate cancer
- adverse drug
- ankylosing spondylitis
- drug delivery
- magnetic resonance imaging
- crispr cas
- data analysis
- interstitial lung disease
- emergency department
- systemic lupus erythematosus
- deep learning
- idiopathic pulmonary fibrosis
- contrast enhanced